0001654954-18-007663.txt : 20180713 0001654954-18-007663.hdr.sgml : 20180713 20180713171200 ACCESSION NUMBER: 0001654954-18-007663 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180713 DATE AS OF CHANGE: 20180713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-205444 FILM NUMBER: 18953105 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 424B3 1 cvm_424b3.htm PRIMARY DOCUMENT Untitled Document
 
 
PROSPECTUS SUPPLEMENT
 Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement dated December 8, 2016)
 Registration No. 333-205444
 
CEL-SCI CORPORATION
Series DD and Series EE Warrants
 
 
On July 10, 2018 the Company extended the expiration date of its Series DD and Series EE warrants until the close of business on December 10, 2018. The Series DD and Series EE warrants were issued as part of a financing on December 8, 2016. As a result of the reverse stock split approved by the Company’s shareholders and adopted by the Company’s directors:
 
●
the holders of the Series DD warrants are entitled to purchase 1,360,960 shares of the Company’s common stock at an exercise price of $4.50 per share; and
 
●
the holders of the Series EE warrants are entitled to purchase 1,360,960 shares of the Company’s common stock at an exercise price of $4.50 per share.
 
 
 
 
 
  Prospectus Supplement dated July 11, 2018